噻托溴铵联合沙美特罗替卡松吸入对重度稳定期COPD患者的治疗价值研究.docVIP

噻托溴铵联合沙美特罗替卡松吸入对重度稳定期COPD患者的治疗价值研究 　　【摘要】 目的 研究噻托溴铵联合沙美特罗替卡松吸入对重度稳定期慢性阻塞性肺疾病（COPD）患者的治疗价值。方法 70例重度稳定期COPD患者， 随机分为M组和M+S组， 各35例。M组给予沙美特罗替卡松吸入治疗， M+S组给予噻托溴铵联合沙美特罗替卡松吸入治疗。比较两组疗效、治疗前后用力肺活量（FVC）、第一秒用力呼气容积（FEV1）、FEV1/ FVC的差异。结果 M+S组总有效率（91.43%）高于M组（68.57%） （P0.05）。治疗后两组FVC、FEV1、FEV1/ FVC均较治疗前改善， M+S组改善程度优于M组， 差异均具有统计学意义（P0.05）。结论 噻托溴铵联合沙美特罗替卡松吸入对重度稳定期COPD患者的治疗价值确切， 可有效改善患者临床症状和肺功能， 值得推广。 　　【关键词】 噻托溴铵；沙美特罗替卡松；重度稳定期慢性阻塞性肺疾病 　　DOI：10.14163/j.cnki.11-5547/r.2016.27.003 　　【Abstract】 Objective To research treatment value by tiotropium bromide combined with salmeterol and fluticasone propionate by inhalation for severe stable chronic obstructive pulmonary disease （COPD） patients. Methods A total of 70 patients with severe stable COPD were randomly divided into group M and group M+S， with 35 cases in each group. Group M received salmeterol and fluticasone propionate by inhalation for treatment， and group M+S received tiotropium bromide combined with salmeterol and fluticasone propionate by inhalation. Comparison was made on curative effect， forced vital capacity （FVC）， forced expiratory volume in 1 second （FEV1） and FEV1/FVC before and after treatment between the two groups. Results Group M+S had higher total effective rate （91.43%） than group M （68.57%） （P0.05）. After treatment， both groups had improved FVC， FEV1 and FEV1/FVC， while group M+S had better improvement than group M. Their differences all had statistical significance （P0.05）. Conclusion Combination of tiotropium bromide and salmeterol and fluticasone propionate provides precisely curative effect for severe stable COPD patients. This method can effectively improve clinical symptoms and pulmonary function in patients， and it is worth promoting. 　　【Key words】 Tiotropium bromide； Salmeterol and fluticasone propionate； Severe stable chronic obstructive pulmonary disease 　　COPD为常见呼吸道疾病， 患者以咳痰、咳嗽和气促等为临床表现， 气道气流受限。COPD发展至重度期后， 常规治疗效果欠佳， 患者运动耐量和生活质量均受影响， 威胁生命安全[1]。本研究对噻托溴铵联合沙美特罗替卡松吸入对重度稳定期COPD患者的治疗价值进行分析， 报告如下。 　　1 资料